BIOMAT Database Logo BIOMAT Database Logo

Structure-based design of novel dihydroalkoxybenzyloxopyrimidine derivatives as potent nonnucleoside inhibitors of the human immunodeficiency virus reverse transcriptase. 1998

E A Sudbeck, and C Mao, and R Vig, and T K Venkatachalam, and L Tuel-Ahlgren, and F M Uckun
Drug Discovery Program, Hughes Institute, St. Paul, Minnesota 55113, USA.

Two highly potent dihydroalkoxybenzyloxopyrimidine (DABO) derivatives targeting the nonnucleoside inhibitor (NNI) binding site of human immunodeficiency virus (HIV) reverse transcriptase (RT) have been designed based on the structure of the NNI binding pocket and tested for anti-HIV activity. Our lead DABO derivative, 5-isopropyl-2-[(methylthiomethyl)thio]-6-(benzyl)-pyrimidin-4-(1H)-on e, elicited potent inhibitory activity against purified recombinant HIV RT and abrogated HIV replication in peripheral blood mononuclear cells at nanomolar concentrations (50% inhibitory concentration, <1 nM) but showed no detectable cytotoxicity at concentrations as high as 100 microM.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D011744 Pyrimidinones Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O. Pyrimidinone,Pyrimidone,Pyrimidones
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006860 Hydrogen Bonding A low-energy attractive force between hydrogen and another element. It plays a major role in determining the properties of water, proteins, and other compounds. Hydrogen Bonds,Bond, Hydrogen,Hydrogen Bond
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013440 Sulfides Chemical groups containing the covalent sulfur bonds -S-. The sulfur atom can be bound to inorganic or organic moieties. Sulfide,Thioether,Thioethers,Sulfur Ethers,Ethers, Sulfur
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse

Related Publications

E A Sudbeck, and C Mao, and R Vig, and T K Venkatachalam, and L Tuel-Ahlgren, and F M Uckun
New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
June 2009, Journal of medicinal chemistry,
E A Sudbeck, and C Mao, and R Vig, and T K Venkatachalam, and L Tuel-Ahlgren, and F M Uckun
Interface peptides as structure-based human immunodeficiency virus reverse transcriptase inhibitors.
December 1995, The Journal of biological chemistry,
E A Sudbeck, and C Mao, and R Vig, and T K Venkatachalam, and L Tuel-Ahlgren, and F M Uckun
Rational approaches for the design of effective human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitors.
January 2011, Journal of chemical information and modeling,
E A Sudbeck, and C Mao, and R Vig, and T K Venkatachalam, and L Tuel-Ahlgren, and F M Uckun
Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates.
April 1997, Antimicrobial agents and chemotherapy,
E A Sudbeck, and C Mao, and R Vig, and T K Venkatachalam, and L Tuel-Ahlgren, and F M Uckun
The PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
June 1995, Antimicrobial agents and chemotherapy,
E A Sudbeck, and C Mao, and R Vig, and T K Venkatachalam, and L Tuel-Ahlgren, and F M Uckun
A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
February 2007, Antimicrobial agents and chemotherapy,
E A Sudbeck, and C Mao, and R Vig, and T K Venkatachalam, and L Tuel-Ahlgren, and F M Uckun
Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1.
April 1994, Proceedings of the National Academy of Sciences of the United States of America,
E A Sudbeck, and C Mao, and R Vig, and T K Venkatachalam, and L Tuel-Ahlgren, and F M Uckun
TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.
December 2004, Antimicrobial agents and chemotherapy,
E A Sudbeck, and C Mao, and R Vig, and T K Venkatachalam, and L Tuel-Ahlgren, and F M Uckun
Novel aptamer inhibitors of human immunodeficiency virus reverse transcriptase.
June 2008, Oligonucleotides,
E A Sudbeck, and C Mao, and R Vig, and T K Venkatachalam, and L Tuel-Ahlgren, and F M Uckun
Benzophenone derivatives: a novel series of potent and selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
May 1995, Journal of medicinal chemistry,
Copied contents to your clipboard!